Paul Plourde

Paul Plourde, MD, is the vice president for Clinical Oncology Development at Sermonix Pharmaceuticals. Prior to Sermonix, he was the senior vice president of Oncology at AstraZeneca and US head of phase 2, 3, and 3b trials. Paul has 25 years of experience in developing new oncology medications, including breast cancer drugs tamoxifen, anastrozole, and fulvestrant.

Dr Plourde has 33 years of clinical practice experience in endocrinology and internal medicine and has been involved in 8 regulatory drug approvals.

Dr Plourde has affiliations with the American Society of Clinical Oncology, the American Society of Hematology, and the American Society of Pediatric Oncology and Hematology.